(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Re-irradiation for H&N cancers with IMRT and concurrent chemotherapy results in promising local control and survival outcomes in selected patients. Treatment-related toxicity continues to be significant despite improvements in systemic therapy and radiation dose conformality, warranting careful patient selection and target volume delineation.

Vinita Takiar, MD, PhD, Dominic Ma, BS, Adam S. Garden, MD, Beth M. Beadle, MD, PhD, Clifton D. Fuller, MD, PhD, Gary B. Gunn, MD, William H. Morrison, MD, David I. Rosenthal, MD, Jack Phan, MD, PhD; UT MD Anderson Cancer Center

PURPOSE AND OBJECTIVES: The probability of locoregional failure after definitive treatment for cancers in the head and neck (H&N) area approaches 50%, with 80% of such failures occurring within previously high-dose–treated radiation volumes, within 2 years of treatment. Historically, H&N cancers arising in previously irradiated volumes were rarely re-treated with radiotherapy due to toxicity concerns. With improved precision in planning and delivery, re-irradiation is now used with greater frequency. Here, we review and analyze our 15-year institutional experience using only intensity-modulated radiation therapy (IMRT) to treat previously irradiated H&N carcinoma.

MATERIALS AND METHODS: We retrospectively reviewed the records of 227 patients who were re-irradiated to the H&N using IMRT between 1999 and 2014. Radiation-related acute and late toxicity, including events requiring hospitalization or urgent intervention and death were recorded. Outcome variables included gender, age, surgery, chemotherapy, radiotherapy dose, radiotherapy volume, and time between initial irradiation and re-irradiation. 

RESULTS: A total of 206 patients (91%) were treated with definitive intent. Of them, 104 patients (50%) underwent salvage resection and 136 patients (66%) received chemotherapy. Median follow-up after re-irradiation for definitely treated patients was 24.7 months. The 5-year rates of locoregional control, progression-free survival, and overall survival for definitively treated patients were 54%, 25%, and 39%, respectively. Actuarial rates of grade ≥ 3 toxicity were 32% at 2 years and 48% at 5 years, with dysphagia or odynophagia requiring feeding tube placement representing the most common toxicity of grade ≥ 3. On multivariate analysis, concurrent chemotherapy and retreatment site influenced tumor control, whereas response to induction chemotherapy and initial disease site influenced survival. High-dose clinical tumor volume (CTV1) > 50 cc and concurrent chemotherapy were significantly associated with increased grade ≥ 3 toxicity. Notably, patients who were treated to a CTV1 < 25 cc experienced no grade ≥ 3 toxicity.

CONCLUSIONS: Re-irradiation for H&N cancers with IMRT and concurrent chemotherapy results in promising local control and survival outcomes in selected patients. Treatment-related toxicity continues to be significant despite improvements in systemic therapy and radiation dose conformality, warranting careful patient selection and target volume delineation.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content